Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial. - Guglielmetti L; Khan U; Velásquez GE; Gouillou M; Ali MH; Amjad S; Kamal F; Abubakirov A; Ardizzoni E; Baudin E; Bektassov S; Berry C; et al. (The Lancet. Respiratory medicine, 2025)